Abstract
A topical mucoadhesive dosage form was developed for the treatment of infectious oral cavity diseases, consisting of a paste based on a combination of a complex immunoglobulin preparation (CIP) and interferon alpha-2b. CIP within the final formulation demonstrated robust antimicrobial activity against key oral pathogens (Staphylococcus aureus, Streptococcus intermedius, and Fusobacterium nucleatum). An optimal composition was selected that exhibited optimal mucoadhesion and a mucosal retention time of at least 90 min. The final formulation produced no local irritant effects.